Thus this finding is not only confirmatory about the veracity of our data, but supports the continued investigation of mTOR inhibitors for ccRCC; these drugs act through attenuation of an element of the p53 pathway, p21[16], which is anti-apoptotic[11], pro-proliferative[17], and has prognostic value in ccRCC[5]. This evidence concerns the gene MTOR and nonpapillary renal cell carcinoma.